[1]韩宇飞,张裕民,李凤梅,等.甲磺酸阿帕替尼联合培美曲塞、洛铂治疗复发性卵巢癌的短期疗效及临床观察[J].中国计划生育和妇产科,2020,(9):76-80.
　HAN Yufei,ZHANG Yumin,LI Fengmei,et al.The shortterm effect and clinical observation of apatinib mesylate combined with pemetrexed and lobaplatin in the treatment of recurrent ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2020,(9):76-80.
点击复制

甲磺酸阿帕替尼联合培美曲塞、洛铂治疗复发性卵巢癌的短期疗效及临床观察
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2020年9期
页码:
76-80
栏目:
论著与临床
出版日期:
2020-09-25

文章信息/Info

Title:
The shortterm effect and clinical observation of apatinib mesylate combined with pemetrexed and lobaplatin in the treatment of recurrent ovarian cancer
作者:
韩宇飞1; 张裕民2; 李凤梅1; 张萍1; 陈龙1*
1. 266011山东青岛，青岛市市立医院妇科；2. 274000山东菏泽，菏泽市食品药品检验检测研究院
Author(s):
HAN Yufei1; ZHANG Yumin2; LI Fengmei1; ZHANG Ping1; CHEN Long1*
1.Department of Gynecology, Qingdao Municipal Hospital, Qingdao Shandong 266011;2.Food and Drug Inspection and Testing Research Institute,Heze Shandong,274000,P.R.China
关键词:
复发性卵巢癌; 阿帕替尼; 培美曲塞; 洛铂; 有效性; 不良反应
Keywords:
recurrent ovarian cancer;  apatinib;  pemetrexed;  lobaplatin;  effectiveness;  adverse reactions
分类号:
R 73731
摘要:
目的探讨甲磺酸阿帕替尼联合培美曲塞、洛铂治疗复发性卵巢癌的短期临床疗效与不良反应。方法选取2018年4~11月在青岛市市立医院妇科曾接受二线及二线以上化疗治疗失败的复发性卵巢癌患者10例为研究对象，在接受培美曲塞、洛铂化疗的同时给予甲磺酸阿帕替尼（500 mg/d）口服。每3周复查血清肿瘤标记物CA 125，每6周复查CT监测病灶变化,并记录分析药物相关的不良事件。结果10例复发性卵巢癌患者的平均化疗周期数为55 个(5～6个) 。经过1周期的阿帕替尼联合培美曲塞、洛铂化疗治疗后，9例患者的CA 125水平明显下降,经过5周期的治疗后，CA 125水平下降至正常范围内；1例透明细胞癌患者经过4周期的治疗后也呈下降趋势，但仍明显高于正常值。CT结果显示，经过4周期治疗后8例患者病灶缩小＞30 %，经过6周期治疗后，病灶缩小＞50 %；1例黏液性癌患者与1例透明细胞癌患者经过5~6周期治疗后病灶直径未有明显改变。治疗期间发生继发性高血压9例；出现手足综合征6例；出现蛋白尿（2+）9例，出现消化道穿孔1例，其客观缓解率均高于未出现相应并发症的患者。结论甲磺酸阿帕替尼联合培美曲塞、洛铂化疗治疗复发性卵巢癌有效性较好，不良反应可控；患者出现血压升高及蛋白尿或手足综合征可能疗效更好。今后仍需进一步探索该方案的远期疗效，为复发性卵巢癌患者提供更加安全有效的治疗方案。
Abstract:
ObjectiveTo explore the shortterm clinical efficacy and adverse reactions of apatinib mesylate combined with pemetrexed and lobaplatin in the treatment of recurrent ovarian cancer.MethodsFrom April to November 2018, 10 patients with recurrent ovarian cancer who had failed secondline and above chemotherapy in the Department of Gynecology of Qingdao Municipal Hospital were selected as the research subjects, and they were given pemetrexed and lobaplatin simultaneously. Apatinib mesylate (500 mg/d) was taken orally. The serum tumor marker CA 125 was rechecked every 3 weeks, and CT was checked every 6 weeks to monitor changes in the lesions. And record and analyze drugrelated adverse events.ResultsThe average number of chemotherapy cycles for 10 patients with recurrent ovarian cancer was 55 (5~6). After 1 cycle of apatinib combined with pemetrexed and lobaplatin chemotherapy, the CA 125 level of 9 patients decreased significantly. After 5 cycles of treatment, the CA 125 level fell within the normal range; 1 case of clear cell carcinoma after 4 cycles of treatment, it also showed a downward trend, but it was still significantly higher than normal. CT results showed that the lesions of 8 patients shrank>30 % after 4 cycles of treatment, and>50 % after 6 cycles of treatment; 1 patient with mucinous carcinoma and 1 patient with clear cell carcinoma after 5 to 6 cycles of treatment,the diameter of the lesion did not change significantly. During the treatment period, 9 cases of secondary hypertension occurred; 6 cases of handfoot syndrome occurred; 9 cases of proteinuria (2+) occurred, 1 case of digestive tract perforation, and the objective response rate (ORR) was high for patients without corresponding complications.ConclusionApatinib mesylate combined with pemetrexed and lobaplatin are effective in the treatment of recurrent ovarian cancer, with controllable adverse reactions; patients with elevated blood pressure and proteinuria or handfoot syndrome may be more effective. In the future, it is still necessary to further explore the longterm efficacy of this program to provide a safer and more effective treatment program for patients with recurrent ovarian cancer.

参考文献/References:

［1］Jemal A, Siegel R, Xu Jiaquan, et al. Cancer statistics, 2010 ［J］. CAA：Cancer Journal for Clinicians, 2010, 60(5): 277300. ［2］Michael A B. Trials with impact on clinical management: first line ［J］. International Journal of Gynecological Cancer, 2009, 19(Suppl 2):S 55S 62. ［3］罗丹，孔为民．复发性卵巢癌治疗的研究进展 ［J］．癌症进展，2019，17（17）： 2003 2006． ［4］Li Jin, Zhao Xinmin, Chen Lei, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor2 inhibitor YN968D1 in patients with advanced malignancies ［J］. BMC Cancer, 2010, 10: 529. ［5］Lan Chunyan, Yin Wang, Ying Xiong, et al. Apatinib combined with oral etoposide in patients with platinumresistant or platinumrefractory ovarian cancer (AEROC): a phase 2, singlearm, prospective study ［J］. The Lancet Oncology, 2018, 19(9): 12391246. ［6］邵婷，陈秀玮．卵巢癌的病因假说及危险因素和流行病学研究进展 ［J］．中华临床医师杂志（电子版），2013，7（19）：88948897． ［7］Zhao J, Chen Wz, Ma W, et al. Expression and clinical significance of VEGF,P53 and CerbB2 protein in epithelial ovarian tumors ［J］. Hebei Med J, 2015, 37(6): 1013. ［8］吴学元，马巍，任国文，等．肿瘤血管靶向治疗的研究进展 ［J］．现代肿瘤医学，2009，17（1）：121125． ［9］Chen Lin, Wang Shan, Xie Wei, et al. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5BRET via suppressing RET/Src signaling pathway ［J］. Oncotarget, 2016, 7(37): 5923659244. ［10］Ying Wang, Zheng Wenling, Ma Wenli. Lobaplatin inhibits the proliferation of hepatollular carcinoma through P53 apoptosis axis ［J］. Hepatitis Monthly, 2012, 12(10 HCC): 6024. ［11］Xie Chengying, Xu Yongping, Jin Wei, et al. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in nonsmallcell lung cancer ［J］. AntiCancer Drugs, 2012, 23(7): 698705. ［12］张雪梅．紫杉醇联合洛铂化疗方案对晚期初治卵巢癌术后患者早期临床疗效及毒副反应发生率的分析 ［J］．中国计划生育和妇产科，2018，10（2）： 72 75． ［13］Chattopadhyay S,Moran R G,Goldman I D.Pemetrexed:biochemical and cellular pharmacology,mechanisms,and clinical applications ［J］.Molecular Cancer Therapeutics,2007,6(2):404417. ［14］Matulonis U A, Horowitz N S, Campos S M, et al. Phase II study of carboplatin and pemetrexed for the treatment of platinumsensitive recurrent ovarian cancer ［J］. Journal of Clinical Oncology,2008, 26(35): 57615766. ［15］邓小玲，黄山鉴，杨凡．多西他赛联合重组人血管内皮抑素对初治后进展非小细胞肺癌患者的临床评价 ［J］．中国综合临床，2015，31（12）：11171120．

相似文献/References:

[1]李静*,李美林,孙国宏,等.抗血管药物治疗Ⅲ/Ⅳ期和复发性卵巢癌疗效的荟萃分析[J].中国计划生育和妇产科,2018,(6):42.
　LI Jing*,LI Mei-lin,SUN Guo-hong,et al.A meta-analysis of the efficacy of anti-angiogenic agents in thetreatment of stage III / IV and recurrent ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(9):42.
[2]邓黎,梁志清*.卵巢癌手术治疗新进展[J].中国计划生育和妇产科,2019,(10):12.

更新日期/Last Update: 2020-09-25